To compare the efficacy, adverse effects, and patient compliance of latanoprost monotherapy
with unfixed combination therapy with 0.5% timolol maleate and 1% dorzolamide in the
treatment of chronic primary angle-closure glaucoma (CACG), 36 Japanese patients with CACG
following laser iridotomy (LPI) were treated for 12 weeks with instillation of latanoprost alone
or with unfixed combination therapy of 0.5% timolol maleate and 1% dorzolamide hydrochloride.
After 12 weeks of treatment, latanoprost reduced intraocular pressure (IOP) from
22.2 ± 2.0 mmHg to 14.8 ± 1.9 mmHg (33% reduction); timolol maleate and dorzolamide hydrochloride
also reduced IOP from 22.5 ± 2.2 mmHg to 17.1 ± 2.7 mmHg (24% reduction).
Latanoprost monotherapy significantly lowered IOP compared with unfixed combination
therapy of 0.5% timolol maleate and 1% dorzolamide hydrochloride. Furthermore, a systemic
adverse effect of bradycardia was not observed in the latanoprost monotherapy group. Concerning
compliance, no significant difference was observed between the two groups. Thus,
latanoprost monotherapy is more effective than unfixed combination therapy with 0.5% timolol
maleate and 1% dorzolamide in the treatment of CACG following relief of pupillary
block in Japanese patients.
